MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Merck & Co., Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$143.63−2.32 (-1.59%)
Close on Oct 19, 2026
- Market cap
- $354.77B
- P/E (TTM)
- 114.9
- Dividend yield
- 2.28%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
80.3%
1.98B of 2.47B shares
Institutional holders
3,824
209 new, 116 sold out
Net institutional buying
56M
In Q2 2026
Insider trades, 12 months
0 buys · 35 sales
Net sold $72.01M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 201,836,434 | 8.00% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 186,323,766 | 7.53% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MRK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 226,999,837 | 9.20% | $29.17B | +1,169,507 | 0.43% |
| Vanguard Capital Management LLC | 161,323,174 | 6.54% | $20.73B | +335,550 | 0.44% |
| State Street Corp | 120,413,256 | 4.88% | $15.57B | +1,087,583 | 0.46% |
| Wellington Management Group Llp | 86,249,283 | 3.50% | $11.08B | +1,934,312 | 1.91% |
| Vanguard Portfolio Management LLC | 67,738,969 | 2.75% | $8.70B | +434,664 | 0.39% |
| Geode Capital Management, LLC | 60,744,214 | 2.46% | $7.79B | +1,186,060 | 0.42% |
| Charles Schwab Investment Management Inc | 54,365,289 | 2.20% | $6.99B | +4,600,064 | 0.93% |
| Morgan Stanley | 48,641,158 | 1.97% | $6.25B | +1,008,671 | 0.33% |
| FMR LLC | 45,440,355 | 1.84% | $5.84B | +924,345 | 0.25% |
| JPMorgan Chase & Co | 43,886,420 | 1.78% | $5.68B | −9,086,563 | 0.31% |
| Fisher Asset Management, LLC | 38,516,263 | 1.56% | $4.95B | +12,079,979 | 1.47% |
| Norges Bank | 36,983,784 | 1.50% | $4.75B | New | 0.47% |
| Bank Of America Corp /De/ | 30,535,208 | 1.24% | $3.92B | −239,013 | 0.25% |
| Northern Trust Corp | 26,275,718 | 1.07% | $3.38B | −814,305 | 0.39% |
| Goldman Sachs Group Inc | 22,075,139 | 0.89% | $2.84B | +1,941,760 | 0.25% |
| Franklin Resources Inc | 19,548,585 | 0.79% | $2.51B | +3,281,380 | 0.54% |
| UBS Asset Management Americas Inc | 19,547,171 | 0.79% | $2.51B | −867,648 | 0.46% |
| Legal & General Group Plc | 18,873,343 | 0.76% | $2.43B | −665,202 | 0.51% |
| Invesco Ltd. | 18,611,171 | 0.75% | $2.39B | −3,243,930 | 0.19% |
| Price T Rowe Associates Inc /Md/ | 18,518,796 | 0.75% | $2.38M | −4,524,046 | 0.24% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 3,824 | 1.98B | 80.3% | 209 / 1632 | 1492 / 116 | 135M | 80M |
| Q1 2026 | 3,796 | 1.93B | 78.3% | 317 / 1461 | 1587 / 123 | 361M | 144M |
| Q4 2025 | 3,658 | 1.97B | 80.0% | 549 / 1377 | 1402 / 130 | 181M | 144M |
| Q3 2025 | 3,310 | 1.94B | 78.7% | 192 / 1364 | 1420 / 149 | 112M | 152M |
| Q2 2025 | 3,325 | 1.98B | 80.4% | 179 / 1299 | 1533 / 253 | 122M | 114M |
| Q1 2025 | 3,447 | 1.98B | 80.3% | 183 / 1347 | 1596 / 275 | 150M | 134M |
| Q4 2024 | 3,601 | 1.99B | 80.5% | 390 / 1321 | 1574 / 208 | 153M | 135M |
| Q3 2024 | 3,485 | 1.99B | 80.5% | 148 / 1525 | 1419 / 161 | 304M | 93M |
| Q2 2024 | 3,539 | 1.98B | 80.4% | 177 / 1607 | 1362 / 119 | 83M | 148M |
| Q1 2024 | 3,532 | 2.06B | 83.4% | 260 / 1412 | 1487 / 112 | 146M | 83M |
| Q4 2023 | 3,429 | 2.01B | 81.3% | 380 / 1245 | 1482 / 107 | 156M | 64M |
| Q3 2023 | 3,209 | 1.92B | 77.9% | 148 / 1296 | 1405 / 148 | 63M | 76M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MRK | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 78,411,374 | 3.18% | $10.08B | 0.44% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 63,996,884 | 2.59% | $8.22B | 0.49% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 33,973,743 | 1.38% | $4.37B | 0.49% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 31,762,503 | 1.29% | $3.77B | 0.45% | May 31, 2026 |
| Schwab U.S. Dividend Equity ETF | 30,860,833 | 1.25% | $3.66B | 3.86% | May 31, 2026 |
| Vanguard Value Index Fund | 23,507,703 | 0.95% | $3.02B | 1.19% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 17,448,577 | 0.71% | $2.24B | 5.52% | Jun 30, 2026 |
| Vanguard Health Care Fund | 15,950,834 | 0.65% | $2.08B | 5.44% | Jul 31, 2026 |
| Vanguard Dividend Appreciation Index Fund | 13,974,148 | 0.57% | $1.82B | 1.39% | Jul 31, 2026 |
| Vanguard Institutional Index Fund | 13,407,864 | 0.54% | $1.72B | 0.49% | Jun 30, 2026 |
| Vanguard Equity Income Fund | 12,367,541 | 0.50% | $1.59B | 2.43% | Jun 30, 2026 |
| Vanguard High Dividend Yield Index Fund | 9,961,116 | 0.40% | $1.30B | 1.31% | Jul 31, 2026 |
| Vanguard Wellington Fund | 9,932,268 | 0.40% | $1.18B | 0.95% | May 31, 2026 |
| Washington Mutual Investors Fund | 8,487,046 | 0.34% | $1.11B | 0.51% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 7,454,549 | 0.30% | $885.00M | 4.66% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert M. Davis | Chairman, CEO & President, Director | 450,351 | 0.02% | May 7, 2026 |
| Gaurav K. Gupta | EVP, CIDO | 750 | 0.00% | Sep 1, 2026 |
| Chirfi Guindo | EVP, Access, Policy & Comms | 36,670 | 0.00% | Aug 13, 2026 |
| Jennifer Zachary | EVP, General Counsel | 125,824 | 0.01% | Aug 13, 2026 |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 111,488 | 0.00% | Aug 12, 2026 |
| David R. Maraldo | EVP & Pres. MMD | 29,258 | 0.00% | Aug 7, 2026 |
| David Michael Williams | EVP,Chief Info&Digital Officer | 31,716 | 0.00% | Aug 7, 2026 |
| Dalton E. Smart III | SVP Fin. - Global Controller | 9,388 | 0.00% | May 7, 2026 |
| Brian Foard | EVP, Specialty, Pharma, & ID | – | – | May 7, 2026 |
| Dean Y. Li | Executive VP & President, MRL | 94,431 | 0.00% | May 7, 2026 |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 21,895 | 0.00% | May 7, 2026 |
| Betty D. Larson | EVP, Chief HR Officer | 13,774 | 0.00% | May 7, 2026 |
| Caroline Litchfield | EVP & CFO | 92,301 | 0.00% | May 7, 2026 |
| Sanat Chattopadhyay | Exe V-P & Pres. MMD | 200,675 | 0.01% | May 1, 2026 |
| Joseph Romanelli | President, Human Health Int?l | 28,739 | 0.00% | Jan 28, 2026 |
| Cristal N. Downing | Chief Comm. & Public Afrs Ofcr | 0 | – | Nov 12, 2025 |
| Mary Ellen Coe | Director | 10 | 0.00% | Jul 1, 2026 |
| Surendralal Lanca Karsanbhai | Director | 1 | 0.00% | Jul 1, 2026 |
| Christine E. Seidman | Director | 100 | 0.00% | Jul 1, 2026 |
| Inge G. Thulin | Director | 2,933 | 0.00% | Jun 2, 2026 |
| Pamela J. Craig | Director | 1,715 | 0.00% | Jun 2, 2026 |
| Patricia F. Russo | Director | 13,148 | 0.00% | Jun 2, 2026 |
| Kathy J. Warden | Director | 500 | 0.00% | Jun 2, 2026 |
| Douglas M. Baker Jr | Director | 16,000 | 0.00% | Jun 2, 2026 |
| Risa J. Lavizzo-Mourey | Director | 1,000 | 0.00% | Jun 2, 2026 |
| Thomas H. Glocer | Director | 5,100 | 0.00% | Jun 2, 2026 |
| Paul Rothman | Director | 100 | 0.00% | Jun 2, 2026 |
| Stephen Mayo | Director | 100 | 0.00% | Jun 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Chirfi Guindo EVP, Access, Policy & Comms | Aug 13, 2026 | Sale | −10,000 | $135.00 | $1.35M | 36,613 |
| Jennifer Zachary EVP, General Counsel | Aug 12, 2026 | Option exercise | +13,433 | $84.71 | $1.14M | 125,824 |
| Jennifer Zachary EVP, General Counsel | Aug 12, 2026 | Sale | −80,315 | $133.46 | $10.72M | 45,509 |
| Jennifer Zachary EVP, General Counsel | Aug 12, 2026 | Option exercise | +41,494 | $117.89 | $4.89M | 112,391 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 12, 2026 | Sale | −600 | $132.04 | $79.22K | 110,167 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 12, 2026 | Sale | −11,099 | $131.61 | $1.46M | 110,767 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 11, 2026 | Sale | −5,427 | $132.35 | $718.26K | 121,866 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 11, 2026 | Sale | −7,410 | $131.33 | $973.16K | 127,293 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 10, 2026 | Sale | −20,784 | $130.43 | $2.71M | 134,703 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 6, 2026 | Sale | −4,945 | $130.23 | $643.99K | 155,787 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 6, 2026 | Sale | −300 | $131.02 | $39.31K | 155,487 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 6, 2026 | Sale | −805 | $131.02 | $105.47K | 160,732 |
| Chirfi Guindo EVP, Access, Policy & Comms | Aug 6, 2026 | Sale | −15,000 | $131.00 | $1.97M | 46,613 |
| David R. Maraldo EVP & Pres. MMD | Aug 5, 2026 | Option exercise | +2,686 | $84.71 | $227.53K | 20,898 |
| David R. Maraldo EVP & Pres. MMD | Aug 5, 2026 | Option exercise | +6,311 | $73.73 | $465.31K | 24,523 |
| David R. Maraldo EVP & Pres. MMD | Aug 5, 2026 | Sale | −6,311 | $128.72 | $812.35K | 18,212 |
| David R. Maraldo EVP & Pres. MMD | Aug 5, 2026 | Sale | −2,686 | $128.72 | $345.74K | 18,212 |
| David R. Maraldo EVP & Pres. MMD | Aug 5, 2026 | Sale | −9,709 | $128.72 | $1.25M | 18,212 |
| David R. Maraldo EVP & Pres. MMD | Aug 5, 2026 | Option exercise | +9,709 | $87.10 | $845.65K | 27,921 |
| David Michael Williams EVP,Chief Info&Digital Officer | Aug 5, 2026 | Sale | −13,542 | $128.77 | $1.74M | 31,716 |
| David Michael Williams EVP,Chief Info&Digital Officer | Aug 5, 2026 | Option exercise | +4,600 | $77.62 | $357.05K | 36,316 |
| David Michael Williams EVP,Chief Info&Digital Officer | Aug 5, 2026 | Sale | −4,600 | $128.77 | $592.34K | 31,716 |
| David Michael Williams EVP,Chief Info&Digital Officer | Aug 5, 2026 | Option exercise | +13,542 | $75.36 | $1.02M | 45,258 |
| David Michael Williams EVP,Chief Info&Digital Officer | Aug 5, 2026 | Sale | −34,705 | $128.77 | $4.47M | 31,716 |
| David Michael Williams EVP,Chief Info&Digital Officer | Aug 5, 2026 | Option exercise | +34,705 | $73.73 | $2.56M | 66,421 |
| Dalton E. Smart III SVP Fin. - Global Controller | May 2, 2026 | Tax withholding | −132 | $112.16 | $14.81K | 9,388 |
| Dalton E. Smart III SVP Fin. - Global Controller | May 2, 2026 | Option exercise | +383 | $112.16 | $42.96K | 9,520 |
| David R. Maraldo EVP & Pres. MMD | May 2, 2026 | Option exercise | +552 | $112.16 | $61.91K | 18,371 |
| David R. Maraldo EVP & Pres. MMD | May 2, 2026 | Tax withholding | −159 | $112.16 | $17.83K | 18,212 |
| Betty D. Larson EVP, Chief HR Officer | Apr 30, 2026 | Tax withholding | −5,143 | $110.95 | $570.62K | 13,774 |
| Betty D. Larson EVP, Chief HR Officer | Apr 30, 2026 | Option exercise | +11,350 | $110.95 | $1.26M | 18,917 |
| Dalton E. Smart III SVP Fin. - Global Controller | Apr 30, 2026 | Option exercise | +464 | $110.95 | $51.48K | 9,296 |
| Dalton E. Smart III SVP Fin. - Global Controller | Apr 30, 2026 | Tax withholding | −159 | $110.95 | $17.64K | 9,137 |
| Johannes Jacobus Oosthuizen EVP, Oncology & Int?l | Apr 29, 2026 | Option exercise | +1,377 | $110.03 | $151.51K | 22,574 |
| Johannes Jacobus Oosthuizen EVP, Oncology & Int?l | Apr 29, 2026 | Tax withholding | −679 | $110.03 | $74.71K | 21,895 |
| Caroline Litchfield EVP & CFO | Apr 29, 2026 | Option exercise | +3,935 | $110.03 | $432.97K | 94,239 |
| Caroline Litchfield EVP & CFO | Apr 29, 2026 | Tax withholding | −1,938 | $110.03 | $213.24K | 92,301 |
| Betty D. Larson EVP, Chief HR Officer | Apr 29, 2026 | Option exercise | +2,085 | $110.03 | $229.41K | 8,282 |
| Betty D. Larson EVP, Chief HR Officer | Apr 29, 2026 | Tax withholding | −715 | $110.03 | $78.67K | 7,567 |
| Jennifer Zachary EVP, General Counsel | Apr 29, 2026 | Option exercise | +2,951 | $110.03 | $324.70K | 72,351 |
| Jennifer Zachary EVP, General Counsel | Apr 29, 2026 | Tax withholding | −1,454 | $110.03 | $159.98K | 70,897 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Apr 29, 2026 | Tax withholding | −1,241 | $110.03 | $136.55K | 161,537 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Apr 29, 2026 | Option exercise | +2,518 | $110.03 | $277.06K | 162,778 |
| Chirfi Guindo EVP, Access, Policy & Comms | Apr 29, 2026 | Option exercise | +1,967 | $110.03 | $216.43K | 62,582 |
| Chirfi Guindo EVP, Access, Policy & Comms | Apr 29, 2026 | Tax withholding | −969 | $110.03 | $106.62K | 61,613 |
| David Michael Williams EVP,Chief Info&Digital Officer | Apr 29, 2026 | Option exercise | +1,377 | $110.03 | $151.51K | 32,395 |
| David Michael Williams EVP,Chief Info&Digital Officer | Apr 29, 2026 | Tax withholding | −679 | $110.03 | $74.71K | 31,716 |
| Sanat Chattopadhyay Exe V-P & Pres. MMD | Apr 29, 2026 | Tax withholding | −1,130 | $110.03 | $124.33K | 15,347 |
| Sanat Chattopadhyay Exe V-P & Pres. MMD | Apr 29, 2026 | Option exercise | +2,597 | $110.03 | $285.75K | 16,477 |
| Dalton E. Smart III SVP Fin. - Global Controller | Apr 29, 2026 | Option exercise | +944 | $110.03 | $103.87K | 9,156 |
| Dalton E. Smart III SVP Fin. - Global Controller | Apr 29, 2026 | Tax withholding | −324 | $110.03 | $35.65K | 8,832 |
| Robert M. Davis Chairman, CEO & President, Director | Apr 29, 2026 | Option exercise | +13,300 | $110.03 | $1.46M | 456,902 |
| Robert M. Davis Chairman, CEO & President, Director | Apr 29, 2026 | Tax withholding | −6,551 | $110.03 | $720.81K | 450,351 |
| Dean Y. Li Executive VP & President, MRL | Apr 29, 2026 | Tax withholding | −2,326 | $110.03 | $255.93K | 94,431 |
| Dean Y. Li Executive VP & President, MRL | Apr 29, 2026 | Option exercise | +4,722 | $110.03 | $519.56K | 96,757 |
| Chirfi Guindo Chief Marketing Officer | Feb 12, 2026 | Sale | −10,000 | $121.46 | $1.21M | 60,615 |
| Dean Y. Li Executive VP & President, MRL | Feb 10, 2026 | Sale | −10,235 | $117.52 | $1.20M | 92,035 |
| Chirfi Guindo Chief Marketing Officer | Feb 9, 2026 | Sale | −10,000 | $118.41 | $1.18M | 70,615 |
| Jennifer Zachary EVP, General Counsel | Feb 9, 2026 | Sale | −25,946 | $119.15 | $3.09M | 68,916 |
| Jennifer Zachary EVP, General Counsel | Feb 9, 2026 | Option exercise | +56,792 | $119.15 | $6.77M | 125,708 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Guindo Chirfi Officer | Aug 13, 2026 | 10,000 | $1.35M | Aug 13, 2026 | Restricted Stock Vesting Under a Registered Plan |
| L. Zachary Jennifer Officer | Aug 12, 2026 | 80,315 | $10.72M | Aug 12, 2026 | Exercise of Options Under a Registered Plan |
| Robert Deluca Richard Jr Officer | Aug 12, 2026 | 11,699 | $1.54M | Aug 12, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Robert Deluca Richard Jr Officer | Aug 11, 2026 | 12,837 | $1.69M | Aug 11, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Robert Deluca Richard Jr Officer | Aug 10, 2026 | 20,784 | $2.71M | Aug 10, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Guindo Chirfi Officer | Aug 6, 2026 | 15,000 | $1.97M | Aug 6, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Robert Deluca Richard Jr Officer | Aug 6, 2026 | 6,050 | $788.77K | Aug 6, 2026 | Restricted Stock Vesting Under a Registered Plan |
| M. Williams David Officer | Aug 5, 2026 | 52,847 | $6.81M | Aug 5, 2026 | Exercise of Options Under a Registered Plan |
| Maraldo David Officer | Aug 5, 2026 | 18,706 | $2.41M | Aug 5, 2026 | Exercise of Options Under a Registered Plan |
| Guindo Chirfi Officer | Feb 13, 2026 | 20,000 | $2.37M | Feb 9, 2026 | Restricted stock vesting under a registered plan |
| Li Dean Officer | Feb 10, 2026 | 10,235 | $1.20M | Feb 10, 2026 | Restricted stock vesting under a registered plan |
| Zachary Jennifer Officer | Feb 9, 2026 | 121,573 | $14.49M | Feb 9, 2026 | Exercise of options under a registered plan |
| Guindo Chirfi Officer | Feb 9, 2026 | 20,000 | $2.37M | Feb 9, 2026 | Restricted stock vesting under a registered plan |
| Robert Deluca Richard Jr. Officer | Feb 6, 2026 | 37,685 | $4.56M | Feb 6, 2026 | Restricted stock vesting under a registered plan |
| Williams David Officer | Feb 6, 2026 | 5,000 | $609.53K | Feb 6, 2026 | Exercise of options under a registered plan |